Dr. Ou Bai: Interpreting the BTKi Consensus for Indolent Lymphomas in Greater China region丨The 5th Tianjin International Lymphoma Academic Conference

Dr. Ou Bai: Interpreting the BTKi Consensus for Indolent Lymphomas in Greater China region丨The 5th Tianjin International Lymphoma Academic Conference

2024.10.13
From September 6th to 8th, 2024, the 5th Tianjin International Lymphoma Academic Conference was successfully held. The conference featured 12 thematic sessions covering topics such as immunotherapy, translational research, and new drug development, creating a platform for promoting international academic exchange and collaboration. During the event, Hematology Frontier invited Dr. Ou Bai from The First Bethune Hospital of Jilin University to discuss the content of the Greater China region BTK Inhibitor Consensus on indolent lymphomas.
Dr. He Huang and Didier Blaise: Exploring Breakthroughs in Cellular Therapy from Sino-French Perspectives

Dr. He Huang and Didier Blaise: Exploring Breakthroughs in Cellular Therapy from Sino-French Perspectives

2024.10.13
The 11th Sino-French Hematology Academic Conference, organized by the Chinese Medical Doctor Association, recently took place in Tianjin, drawing hundreds of leading experts and scholars in the field of hematology from around the world. During the conference, Hematology Frontier invited Dr. He Huang from The First Affiliated Hospital, Zhejiang University School of Medicine and Dr. Didier Blaise from the Hematology Institute of Aix-Marseille University in France to engage in a dialogue on the challenges and opportunities in new cellular therapies for hematologic malignancies. Here are the key insights from their conversation.
ESMO 2024丨Dr. Junyuan Qi: Cutting Through the Fog, Promising Phase I Results for the New BCL-2 Inhibitor in R/R NHL and AML

ESMO 2024丨Dr. Junyuan Qi: Cutting Through the Fog, Promising Phase I Results for the New BCL-2 Inhibitor in R/R NHL and AML

2024.10.12
From September 13th to 17th, the 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held in Barcelona, Spain. As one of the world's top oncology conferences, it brought together experts and scholars from across the globe to share cutting-edge research findings and discuss future directions. At the session dedicated to hematologic malignancies, Dr. Junyuan Qi from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, presented the first-in-human study of the BCL-2 inhibitor TQB3909 in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) and acute myeloid leukemia (AML), showing promising results. Hematology Frontier invited Professor Qi to provide an in-depth analysis of the study and discuss the future clinical applications and research directions for this novel BCL-2 inhibitor.
Dr. Yao Zhu: Tailoring Prostate Cancer Treatment in China, Fudan University Shanghai Cancer Center’s Team Explores Strategies to Benefit More Patients

Dr. Yao Zhu: Tailoring Prostate Cancer Treatment in China, Fudan University Shanghai Cancer Center’s Team Explores Strategies to Benefit More Patients

2024.10.12
Due to factors such as early screening, drug accessibility, and genetic differences, prostate cancer characteristics in China differ from those in Western countries. In recent years, with China's aging population, the incidence and mortality of prostate cancer have risen significantly, increasing the disease burden. At the recent CSCO Annual Meeting, Urology Frontier invited Dr. Yao Zhu from Fudan University Shanghai Cancer Center to share insights on the characteristics of prostate cancer in China, the latest research progress at Fudan, and the value of clinical research by physicians.
CUA 2024丨Dr. Jian Huang Shares Key Areas of Focus at the CUA Annual Meeting and Sun Yat-sen Memorial Hospital ’s Bladder Cancer Research

CUA 2024丨Dr. Jian Huang Shares Key Areas of Focus at the CUA Annual Meeting and Sun Yat-sen Memorial Hospital ’s Bladder Cancer Research

2024.10.12
The 31st Urology Academic Conference, organized by the Chinese Medical Association and the Chinese Urological Association (CUA), was held from September 19 to 22, 2024, at the National Convention Center in Tianjin. This event brought together leading urology experts from China and abroad to discuss the latest advances in clinical research and surgical treatment. After the conference, Urology Frontier invited Dr. Jian Huang, Chair of the CUA and Director of Urology at Sun Yat-sen Memorial Hospital, Sun Yat-sen University, to share insights on the meeting's focus areas, the application of artificial intelligence (AI) in bladder cancer, and the research directions of his team.
Dr. Qiang Wei: Precision Endocrine Therapy for Prostate Cancer Enters a New Era as the West China Hospital Continues to Pioneer Diagnostic

Dr. Qiang Wei: Precision Endocrine Therapy for Prostate Cancer Enters a New Era as the West China Hospital Continues to Pioneer Diagnostic

2024.10.12
Prostate cancer is one of the most common malignancies in men, with endocrine therapy being a standard treatment approach. However, it often comes with some side effects. Recently, the 31st Annual Urology Conference, hosted by the Chinese Medical Association and the Chinese Urological Association (CUA), was held from September 19-22, 2024, at the Tianjin National Convention Center. Following the event, Urology Frontier invited Dr. Qiang Wei from West China Hospital, Sichuan University to share insights on the latest advancements in endocrine therapy for prostate cancer, side effect management, and the future research directions of his team.